Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Safety issues with statin therapy.

Robert L Talbert1

  • 1College of Pharmacy, University of Texas at Austin, USA. Talbert@uthscsa.edu

Journal of the American Pharmacists Association : Japha
|August 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide association analysis of common genetic variants of resistant hypertension.

The pharmacogenomics journal·2018
Same author

Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes).

Stroke·2017
Same author

CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.

Journal of the American Heart Association·2015
Same author

Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2015
Same author

In Memory of Charles Anthony Walton, Ph.D., FCCP 1926-2014.

Pharmacotherapy·2014
Same author

ASA failure: does the combination ASA/clopidogrel confer better long-term vascular protection?

Neurology·2014
Same journal

Assessment of comprehensive medication management incorporating a patient-completed medical and medication history form in community practice.

Journal of the American Pharmacists Association : JAPhA·2026
Same journal

Characterizing how community pharmacy teams engage with social drivers of health (SDOH) during routine workflow: A report from the medication safety research network of Indiana (Rx-SafeNet).

Journal of the American Pharmacists Association : JAPhA·2026
Same journal

Geographic disparities in board-certified ambulatory care pharmacists in Appalachia.

Journal of the American Pharmacists Association : JAPhA·2026
Same journal

Development of consensus criteria for problematic medications in active duty service members.

Journal of the American Pharmacists Association : JAPhA·2026
Same journal

Barriers and facilitators to pharmacy-based methadone dosing and dispensing: Semi-structured interviews with pharmacists.

Journal of the American Pharmacists Association : JAPhA·2026
Same journal

A bibliometric analysis describing the global scope of pharmacist roles (2000-2024).

Journal of the American Pharmacists Association : JAPhA·2026
See all related articles

Statin therapy, while beneficial for cardiovascular health, carries risks like liver damage and muscle pain. Careful patient selection and monitoring can mitigate these statin side effects.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Toxicology

Background:

  • Statin therapy is increasingly prescribed for lipid management and cardiovascular disease prevention.
  • Growing patient numbers necessitate a thorough understanding of potential adverse effects.
  • Identifying and managing statin-related toxicities is crucial for patient safety.

Purpose of the Study:

  • To outline significant adverse effects of statin therapy.
  • To explore the mechanisms behind statin toxicity and drug interactions.
  • To propose strategies for improving the safety profile of statin use.

Main Methods:

  • Review of large-scale clinical trials and governmental data.
  • Analysis of recent studies focusing on statin safety.

Related Experiment Videos

  • Expert synthesis of available evidence by the author.

    • Main Results:

    • Hepatotoxicity and myopathy are the most significant adverse effects associated with statins.
    • Statins rarely cause severe liver dysfunction; elevations in transaminases are typically reversible.
    • Statin-associated myopathy risk increases with co-existing factors like advanced age and renal impairment.
    • Drug interactions are a concern, particularly with statins metabolized by cytochrome P450 3A4.

    Conclusions:

    • The cardiovascular benefits of statins generally outweigh their risks.
    • For high-risk patients (elderly, polypharmacy), selecting statins with lower interaction potential is advisable.